ADVANZ PHARMA Corp. Limited
https://www.advanzpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ADVANZ PHARMA Corp. Limited
PolyPid’s D-PLEX100 May Have Way Forward Despite Phase III Miss
The SHIELD I trial, for preventing surgical site infections, did not meet its primary and key secondary endpoints, but a subgroup analysis did, while COVID-19 may have muddled results.
Kyorin Pharma To Shut Down US Subsidiary ActivX
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
Eisai To Shut Down H3 In Global R&D Restructuring
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- ADVANZ PHARMA
- ADVANZ PHARMA Corp. Limited
- Amdipharm Mercury Limited
- Concordia Healthcare Corp.
- Concordia International Corp.
- Concordia Laboratories, Inc.
- Concordia Pharmaceuticals, Inc.
- Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
- Correvio Pharma Corp
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice